Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new NIHR funded trial will compare whether either fixing the broken bone or replacing the hip joint gives a better result for people over 60

© Twinsterphoto/Shutterstock

Every year around 70,000 people in the UK, and 1.3 million globally, break their hip. Facing increasingly ageing populations these numbers are projected to rise to more than 100,000 by 2020 in the UK. The problem is estimated to cause the loss of 1.75 million disability adjusted life years per year globally, and represents 1.4% of the total healthcare burden in established market economies.

A new study, FRUITI, will look at treatments for one specific type of hip fracture. Minimally displaced intracapsular fractures, those that occur at the head of the femur, and may have loss of blood supply to the bone, represent approximately ten to fifteen per cent of all hip fractures. Currently, there are two treatments available. Surgeons either repair the fracture with screws or remove and replace the broken piece of bone, but it's not known which is better for patients.

Xavier Griffin, Associate Professor of Trauma Surgery at NDORMS, University of Oxford, explained: "Treatment of this type of fracture by fixing the broken bone is a quick procedure which has the advantage of preserving the patient's own hip joint. However, healing can be unsuccessful with patients requiring revision surgery in perhaps 30% of cases. Hip replacement surgery eliminates the risk of fixation failure as the femoral neck is replaced. But it is a more major operation with very significant complications of its own including a greater risk of infection, dislocation and periprosthetic fracture."

Developed by a team of patient representatives, clinical experts in trauma orthopaedics, study management specialists, experienced statisticians and health economists, the study will compare the two treatments for people 60 years and over. They will recruit 878 people to the study from 40 hospitals across the UK, and review patients health, walking ability and other daily activities, as well as any complications and specific costs at the outset, and at 6 weeks, 4 months and 1 year after the injury.

Fruiti is funded by the National Institute for Health Research (NIHR).

Similar stories

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.